FibroGen stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 90 to 94.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is FibroGen Stock A Buy?
FibroGen is not currently offering a proper buying opportunity. See if the stock goes on to form a promising consolidation that could ignite a new run.
The biotech company reported 0% earnings growth last quarter, while sales growth came in at -41%.
FibroGen stock earns the No. 214 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Arcturus Therapeutics and Kiniksa Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
